717 related articles for article (PubMed ID: 14556449)
21. Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials.
Harousseau JL; Avet-Loiseau H; Attal M; Charbonnel C; Garban F; Hulin C; Michallet M; Facon T; Garderet L; Marit G; Ketterer N; Lamy T; Voillat L; Guilhot F; Doyen C; Mathiot C; Moreau P
J Clin Oncol; 2009 Dec; 27(34):5720-6. PubMed ID: 19826130
[TBL] [Abstract][Full Text] [Related]
22. [Hematopoietic stem cell transplantation in multiple myeloma].
Vela-Ojeda J; Ruiz-Esparza MA
Rev Invest Clin; 2005; 57(2):305-13. PubMed ID: 16524072
[TBL] [Abstract][Full Text] [Related]
23. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients.
O'Shea D; Giles C; Terpos E; Perz J; Politou M; Sana V; Naresh K; Lampert I; Samson D; Narat S; Kanfer E; Olavarria E; Apperley JF; Rahemtulla A
Bone Marrow Transplant; 2006 Apr; 37(8):731-7. PubMed ID: 16501593
[TBL] [Abstract][Full Text] [Related]
24. High dose chemotherapy and autologous stem cell transplantation in patients with multiple myeloma: the experience of a single haematological unit.
Papanikolaou X; Maltezas D; Repousis P; Athanassopoulos A; Alexia S; Megalakaki K; Kotsopoulou M; Mitsouli-Mentzikof C
J BUON; 2008; 13(2):193-7. PubMed ID: 18555464
[TBL] [Abstract][Full Text] [Related]
25. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma.
Zhang XH; Huang XJ; Liu KY; Xu LP; Liu DH; Chen H; Chen YH; Wang JZ; Han W; Lu DP
Chin Med J (Engl); 2007 Mar; 120(6):463-8. PubMed ID: 17439737
[TBL] [Abstract][Full Text] [Related]
26. [High-dose chemotherapy of patients with multiple myeloma].
Heyll A; Söhngen D; Aul C; Schneider P; Kobbe G; Bauser U; Quenzel EM; Schneider W
Praxis (Bern 1994); 1998 Jun; 87(25-26):879-83. PubMed ID: 9702091
[TBL] [Abstract][Full Text] [Related]
27. Allogeneic and autologous bone marrow transplantation after consolidation therapy in high-risk acute myeloid leukemia in children. Towards a risk-oriented therapy.
Ortega JJ; Díaz de Heredia C; Olivé T; Bastida P; Llort A; Armadans L; Torrabadella M; Massuet L
Haematologica; 2003 Mar; 88(3):290-9. PubMed ID: 12651268
[TBL] [Abstract][Full Text] [Related]
28. Reducing transplant-related mortality after allogeneic hematopoietic stem cell transplantation.
Bacigalupo A; Sormani MP; Lamparelli T; Gualandi F; Occhini D; Bregante S; Raiola AM; di Grazia C; Dominietto A; Tedone E; Piaggio G; Podesta M; Bruno B; Oneto R; Lombardi A; Frassoni F; Rolla D; Rollandi G; Viscoli C; Ferro C; Garbarino L; Van Lint MT
Haematologica; 2004 Oct; 89(10):1238-47. PubMed ID: 15477210
[TBL] [Abstract][Full Text] [Related]
29. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.
Kröger N; Perez-Simon JA; Myint H; Klingemann H; Shimoni A; Nagler A; Martino R; Alegre A; Tomas JF; Schwerdtfeger R; Kiehl M; Fauser A; Sayer HG; Leon A; Beyer J; Zabelina T; Ayuk F; San Miguel JF; Brand R; Zander AR
Biol Blood Marrow Transplant; 2004 Oct; 10(10):698-708. PubMed ID: 15389436
[TBL] [Abstract][Full Text] [Related]
30. High-dose therapy and autologous peripheral blood stem cells transplantation followed by a very low reduced intensity regimen with fludarabine + cyclophosphamide and allograft improve complete remission rate in de novo multiple myeloma patients.
Martino M; Console G; Irrera G; Praticò G; Stelitano C; Callea V; Morabito F; Quartarone E; Musolino C; Piro E; Brugiatelli M; Iacopino P
Am J Hematol; 2006 Dec; 81(12):973-8. PubMed ID: 16888786
[TBL] [Abstract][Full Text] [Related]
31. Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma.
Shimoni A; Smith TL; Aleman A; Weber D; Dimopoulos M; Anderlini P; Andersson B; Claxton D; Ueno NT; Khouri I; Donato M; Korbling M; Alexanian R; Champlin R; Giralt S
Bone Marrow Transplant; 2001 Apr; 27(8):821-8. PubMed ID: 11477439
[TBL] [Abstract][Full Text] [Related]
32. Feasibility and outcome of tandem stem cell autotransplants in multiple myeloma.
Galli M; Nicolucci A; Valentini M; Belfiglio M; Delaini F; Crippa C; Barbui AM; Giussani U; Rambaldi A; Barbui T
Haematologica; 2005 Dec; 90(12):1643-9. PubMed ID: 16330437
[TBL] [Abstract][Full Text] [Related]
33. High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience.
Rodriguez J; Caballero MD; Gutierrez A; Gandarillas M; Sierra J; Lopez-Guillermo A; Sureda A; Zuazu J; Marin J; Arranz R; Carreras E; Leon A; De Sevilla AF; San Miguel JF; Conde E;
Haematologica; 2003 Dec; 88(12):1372-7. PubMed ID: 14687990
[TBL] [Abstract][Full Text] [Related]
34. Long-term follow up of patients with multiple myeloma after high-dose chemotherapy and allogeneic stem cell transplantation.
Rabitsch W; Prinz E; Ackermann J; Wöhrer S; Kaufmann H; Seidl S; Keil F; Kalhs P; Greinix H; Gisslinger H; Leitner G; Drach J
Eur J Haematol; 2004 Jan; 72(1):26-31. PubMed ID: 14962259
[TBL] [Abstract][Full Text] [Related]
35. Advances in therapy of multiple myeloma: lessons from acute leukemia.
Barlogie B
Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2605-13. PubMed ID: 10068262
[TBL] [Abstract][Full Text] [Related]
36. High-dose therapy and autologous stem cell transplantation in patients with diffuse large B-cell lymphoma in first complete or partial remission.
Papajik T; Raida L; Faber E; Vondrakova J; Prochazka V; Kubova Z; Skoumalova I; Jarosova M; M LK; Paucek B; Myslivecek M; Neoral C; Oral I; Jarkovsky J; Dusek L; Indrak K
Neoplasma; 2008; 55(3):215-21. PubMed ID: 18348654
[TBL] [Abstract][Full Text] [Related]
37. Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma.
Gahrton G; Iacobelli S; Bandini G; Björkstrand B; Corradini P; Crawley C; Hegenbart U; Morgan G; Kröger N; Schattenberg A; Schönland SO; Verdonck LF; Volin L; de Witte T; Niederwieser D;
Haematologica; 2007 Nov; 92(11):1513-8. PubMed ID: 18024400
[TBL] [Abstract][Full Text] [Related]
38. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
[TBL] [Abstract][Full Text] [Related]
39. Outcome assessment of a population-based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment.
Powles R; Raje N; Milan S; Millar B; Shepherd V; Mehta J; Singhal S; Kulkarni S; Viner C; Gore M; Cunningham D; Treleaven J
Bone Marrow Transplant; 1997 Sep; 20(6):435-43. PubMed ID: 9313875
[TBL] [Abstract][Full Text] [Related]
40. Controversy in multiple myeloma transplants: tandem autotransplants and mini-allografts.
Vesole DH; Simic A; Lazarus HM
Bone Marrow Transplant; 2001 Oct; 28(8):725-35. PubMed ID: 11781623
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
